Home  /  Resource Library  /  THREE-YEAR FOLLOW-UP OF TREATMENT-NAIVE AND PREVIOUSLY TREATED PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA (WM) RECEIVING SINGLE AGENT ZANUBRUTINIB

THREE-YEAR FOLLOW-UP OF TREATMENT-NAIVE AND PREVIOUSLY TREATED PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA (WM) RECEIVING SINGLE AGENT ZANUBRUTINIB

EHA 2020: Results of a phase III study examining zanubrutinib for the treatment of waldenstrom macroglobulinemia.